ProPhase Labs to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
September 07 2021 - 8:30AM
ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and
genomics company, announces today that Chairman and CEO Ted Karkus
will present at the H.C. Wainwright 23rd Annual Global Investment
Conference, which is being held virtually from September 13 – 15,
2021.
Mr. Karkus will deliver his corporate
presentation, which will become available beginning on September 13
at 7:00 AM ET.
Investors can register here:
www.hcwevents.com.
Mr. Karkus will also be available for one-on-one
meetings throughout the conference.
About ProPhase LabsProPhase
Labs (Nasdaq: PRPH) (“ProPhase”) is a diversified biotech and
genomics company that seeks to leverage its CLIA lab services to
provide whole genome sequencing and research direct to consumers
and build a genomics data base to be used for further research. The
Company continues to provide traditional CLIA molecular laboratory
services, including COVID-19 testing. ProPhase Precision Medicine,
Inc., focuses on genomics testing technologies, a comprehensive
method for analyzing entire genomes, including the genes and
chromosomes in DNA. The data obtained from genomic testing can help
to identify inherited disorders and tendencies, help predict
disease risk, help identify expected drug response, and
characterize genetic mutations, including those that drive cancer
progression.
ProPhase Diagnostics offers a broad array of
clinical diagnostic and testing services at its CLIA certified
laboratories. ProPhase Diagnostics serves patients who may have
SARS-CoV-2 (COVID-19) through both saliva and nasal swab methods.
Critical to COVID testing, results are provided in under 24 hours.
ProPhase Diagnostics also offers PCR (polymerase chain reaction)
testing for Influenzas A and B and RSV; as well as antigen and
antibody/immunity tests to broaden its COVID-19 testing beyond
RT-PCR testing.
ProPhase Global Healthcare, Inc. was formed to
seek to expand the Company’s SARS-CoV-2 (COVID-19) testing into
other countries and to pursue additional healthcare-related
initiatives.
ProPhase Labs has decades of experience
researching, developing, manufacturing, distributing, marketing,
and selling OTC consumer healthcare products and dietary
supplements, including dietary supplements under the TK
Supplements® brand. ProPhase actively pursues strategic
investments and acquisition opportunities for other companies,
technologies, and products. For more information,
visit www.ProPhaseLabs.com.
Forward Looking
StatementsExcept for the historical information contained
herein, this document contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements regarding our ability to leverage our
CLIA lab services to provide whole genome sequencing and research
direct to consumers and to build a genomics data base to be used
for further research, our ability to expand our SARS-CoV-2
(COVID-19) testing into other countries, and our goals to pursue
additional healthcare-related initiatives. Management believes that
these forward-looking statements are reasonable as and when made.
However, such forward-looking statements involve known and unknown
risks, uncertainties, and other factors that may cause actual
results to differ materially from those projected in the
forward-looking statements. These risks and uncertainties include
but are not limited to the competitive environment, challenges
relating to entering into new business lines, the failure to obtain
and maintain certain regulatory approvals, our ability to execute
on our business plan, and the risk factors listed from time to time
in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q
and any other SEC filings.
Contact:
CORE IRJules
Abraham917-885-7378julesa@coreir.com
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Sep 2023 to Sep 2024